-
Evogene partners with Systasy and LMU Munich on inflammatory disease therapy
-
Evogene raises $3.4 million through warrant inducement transaction
-
Evogene expands Google Cloud partnership to add AI agents to platform
-
Evogene subsidiary licenses cancer drug BMC128 to Shanghai Lishan
-
Evogene names Dr. Olga Nissan as vice president of business development
-
Evogene (EVGN) Tops Q3 EPS by 12c
-
Casterra and Fantini form partnership for commercial castor farming
-
Evogene (EVGN) Misses Q2 EPS by 24c
-
Evogene partners with Tel Aviv University for metabolic disease drugs
-
Evogene Ltd (EVGN) PT Lowered to $3.50 at Lake Street Capital Markets
-
Evogene (EVGN) Tops Q1 EPS by 35c
-
Evogene (EVGN) to Sell Lavie Bio to ICL
-
Evogene (EVGN) Tops Q4 EPS by 66c
-
Evogene (EVGN) Reports revenue at $1.8 million
-
Evogene (EVGN) Announces Promising New Development Candidate, WTX-921
-
Evogene (EVGN) Files for 3.38M Share Offering by Selling Stockholders
-
Evogene (EVGN) Prices $5.5 Million Registered Direct Offering and Concurrent Private Placement
-
Evogene (EVGN) Tops Q2 EPS by 19c
-
Evogene's (EVGN) Casterra Receives Additional Purchase Order to Supply Castor Seeds to a New African Country

